share_log

贝康医疗拟出资8500万元收购男科IVD公司星博生物51%股权 | 公司要闻

Baycom Medical plans to invest 85 million yuan to acquire a 51% stake in Xingbo Biology, a male IVD company. | Company news

金融界網 ·  Nov 3, 2021 14:06

  China Finance Online Co Ltd news on November 3rdOn November 3, Baycom Medical-B (02170.HK) issued an announcement that the company, as the buyer, entered into an investment agreement with Xingbo and the seller.

Baycom Medical paid 85 million yuan for a 51 per cent stake in Xingbo Biology, including 20.84 per cent, 5.45 per cent and 24.71 per cent held by Xue Zhigang, Hawke Investment and Hu Xiling, respectively. Upon completion of the acquisition, Xingbo Biology will become a non-wholly owned subsidiary of Baycom Medical.

According to the announcement, Xingbo Biology mainly focuses on the research and development, production, sales and technical services of assisted reproductive technology diagnosis and treatment products. Xingbo Biological Strategic layout the strong product mix, strong R & D and marketing capabilities of China's reproductive genetics medical device market, as well as a senior management team with rich experience and insight into China's broader reproductive genetics market and the overall medical device industry.

Baikang Medical believes that Xingbo's business can provide synergy for the company's business, and that Xingbo's products and products under research can further enrich the company's product supply in the undeveloped market in China.

Baycom Medical, the leading innovative platform for assisted reproductive gene testing solutions in China, was listed on the Hong Kong Stock Exchange on February 8, 2021.

As of press time, Bacon Medical-B (02170.HK) was at 9.710 Hong Kong dollars per share, down 1.12%.

  -----------------------------------------------------------

China Finance Online Co Ltd Pharmaceutical Biology Studio is a new capital market + pharmaceutical biological industry media platform built by the center of China Finance Online Co Ltd listed companies, which is committed to connecting pharmaceutical biological enterprises with the capital market and transmitting scientific research and commercial value.

Contact us: xiaofeng.he@jrj.com.cn

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment